Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year?
Baird Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $14
Baird analyst Brian Skorney maintains $Applied Therapeutics(APLT.US)$ with a buy rating, and maintains the target price at $14.According to TipRanks data, the analyst has a success rate of 40.6% and
Applied Therapeutics Shares Are Trading Higher After Leerink Partners and Citigroup Raised Their Respective Price Targets on the Stock.
Citigroup Maintains Buy on Applied Therapeutics, Raises Price Target to $11
Applied Therapeutics Is Maintained at Outperform by Leerink Partners
Applied Therapeutics Analyst Ratings